Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Allergy Thera. (AGY) Regulatory News

Date Source Headline
3rd Mar 2025 7:00 am RNS New Executive Long Term Incentive Awards
27th Feb 2025 7:00 am RNS-R Presentations at 2025 AAAAI / WAO Joint Congress
17th Feb 2025 7:00 am RNS Grass MATA MPL Phase III data published in Allergy
14th Feb 2025 7:00 am RNS Grant of Options
28th Jan 2025 7:00 am RNS Half Year Trading update
22nd Jan 2025 7:00 am RNS PDMR Dealing and Total Voting Rights
15th Jan 2025 7:00 am RNS Director/PDMR Shareholding
19th Dec 2024 1:41 pm RNS Exercise of Options and Total Voting Rights
17th Dec 2024 4:19 pm RNS Block Listing Interim Review
16th Dec 2024 3:33 pm RNS Result of Annual General Meeting
4th Dec 2024 7:00 am RNS Positive Interim Data from PROTECT Trial
27th Nov 2024 7:00 am RNS First Patient Dosed in G308 Paediatric Trial
25th Nov 2024 7:00 am RNS Submission of MAA for Grass MATA MPL
21st Nov 2024 7:00 am RNS Notice of 2024 Annual General Meeting
6th Nov 2024 7:00 am RNS Audited Preliminary Results 2024
21st Oct 2024 7:00 am RNS Commencement of Phase III Paediatric Trial
16th Oct 2024 7:00 am RNS Update on funding
1st Oct 2024 7:00 am RNS Update on funding and preliminary results
17th Sep 2024 7:00 am RNS Progression of patient cohorts in PROTECT Trial
27th Aug 2024 7:00 am RNS Update on funding
22nd Jul 2024 7:01 am RNS Trading update for the year ended 30 June 2024
22nd Jul 2024 7:00 am RNS Appointment of Nominated Adviser and Sole Broker
4th Jul 2024 2:22 pm RNS Launch of new Company Long Term Incentive Plan
27th Jun 2024 7:00 am RNS Appointment of Non-Executive Director
10th Jun 2024 7:00 am RNS Progression of patient cohorts in PROTECT Trial
3rd Jun 2024 7:00 am RNS Successful meetings with Paul Ehrlich Institut
31st May 2024 7:00 am RNS Allergy Therapeutics presents findings at EAACI
7th May 2024 7:00 am RNS Further detail from G306 Phase III field trial
3rd Apr 2024 7:00 am RNS Director Resignation
27th Mar 2024 7:00 am RNS Update on funding
27th Mar 2024 7:00 am RNS Interim Results for six months ended 31 Dec 2023
12th Mar 2024 8:59 am RNS VLP Peanut PROTECT Trial Update
12th Mar 2024 7:00 am RNS VLP Peanut PROTECT Trial Update
11th Mar 2024 7:00 am RNS Appointment of Shaun Furlong to Board of Directors
8th Mar 2024 1:49 pm RNS Result of AGM
14th Feb 2024 7:00 am RNS Half-Year Trading Update 2024
9th Feb 2024 3:07 pm RNS Notice of 2023 Annual General Meeting
30th Jan 2024 7:30 am RNS Restoration - Allergy Therapeutics plc
30th Jan 2024 7:00 am RNS Publication of Annual Report and Accounts 2023
4th Jan 2024 12:29 pm RNS Total Voting Rights
FTSE 100 Latest
Value8,540.97
Change44.98